Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress

Sorafenib is the standard first-line therapeutic treatment for patients with advanced hepatocellular carcinoma (HCC), but its use is hampered by the development of drug resistance. The activation of Akt by sorafenib is thought to be responsible for this resistance. Bufalin is the major active ingred...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:PLoS One
Hlavní autoři: Zhai, Bo, Hu, Fengli, Yan, Haijiang, Zhao, Dali, Jin, Xin, Fang, Taishi, Pan, Shangha, Sun, Xueying, Xu, Lishan
Médium: Artigo
Jazyk:Inglês
Vydáno: Public Library of Science 2015
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4575108/
https://ncbi.nlm.nih.gov/pubmed/26381511
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0138485
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky